Hospital
Thedacare Medical Center - Berlin, INC.
Thedacare Medical Center - Berlin, INC. was paid $9.40M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoTHEDACARE MEDICAL CENTER - BERLIN, INC.
BERLIN, WI 54923
BERLIN, WI 54923
33aNPI1760413777assigned 07/06/2006
33bProvider typeCritical Access Hospital
28Total paid$9.40M
24GClaims251,937
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#8 of 48
Median peer was paid$4.30M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,283 | $1.07M | |
| 2019 | 28,880 | $1.24M | |
| 2020 | 29,788 | $1.11M | |
| 2021 | 44,530 | $1.44M | |
| 2022 | 41,262 | $1.39M | |
| 2023 | 43,298 | $1.70M | |
| 2024incomplete | 31,896 | $1.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 13,346 | 11,252 | $1.78M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 7,643 | 5,881 | $1.09M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 6,535 | 5,597 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 2,810 | 1,913 | $999K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 2,095 | 1,840 | $539K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.4% | 2,135 | 1,800 | $505K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.8% | 2,711 | 1,652 | $448K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.5% | 1,993 | 1,733 | $331K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.2% | 1,202 | 471 | $304K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.0% | 1,986 | 1,491 | $278K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 7,154 | 2,190 | $186K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 17,847 | 12,740 | $144K |
161 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 3,570 | $141K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 124 | $105K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 2,449 | $95K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 427 | $92K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,374 | $90K |
| 87631 | <1% | 958 | $87K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,924 | $81K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 724 | $75K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 188 | $74K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 194 | $59K |
| 80076 | <1% | 10,936 | $54K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,680 | $51K |
| G0378 | Hospital observation service, per hour | <1% | 1,682 | $38K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 155 | $35K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 335 | $34K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 129 | $34K |
| 84484 | <1% | 5,175 | $29K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 527 | $25K |
| 83880 | <1% | 1,602 | $24K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 611 | $23K |
| 80061 | Lipid panel | <1% | 2,167 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,497 | $22K |
| 97162 | <1% | 606 | $18K | |
| 83735 | <1% | 4,810 | $18K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,453 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 126 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,294 | $18K |
| 80306 | <1% | 1,300 | $17K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,090 | $16K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 619 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,543 | $15K |
| 83690 | <1% | 3,075 | $14K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 74 | $14K |
| 81025 | <1% | 1,536 | $14K | |
| 81001 | <1% | 6,447 | $13K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 22 | $13K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 203 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 143 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 880 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 335 | $10K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 335 | $9K |
| 96367 | <1% | 51 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,617 | $8K |
| 83605 | <1% | 1,788 | $8K | |
| 73630 | <1% | 296 | $8K | |
| 74018 | <1% | 246 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 545 | $7K |
| 85610 | <1% | 2,760 | $7K | |
| 85027 | <1% | 1,180 | $6K | |
| 85380 | <1% | 993 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 193 | $6K |
| 82077 | <1% | 773 | $6K | |
| 93356 | <1% | 19 | $6K | |
| 87070 | <1% | 716 | $5K | |
| 70498 | <1% | 13 | $5K | |
| 87040 | <1% | 1,518 | $5K | |
| 87186 | <1% | 861 | $4K | |
| 82550 | <1% | 1,244 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 163 | $4K |
| 36592 | <1% | 862 | $4K | |
| 84703 | <1% | 636 | $4K | |
| 73610 | <1% | 130 | $4K | |
| 82948 | <1% | 1,361 | $4K | |
| 73030 | <1% | 146 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,004 | $3K |
| 82947 | <1% | 928 | $3K | |
| 99000 | <1% | 745 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,829 | $3K |
| 72100 | <1% | 81 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,445 | $3K |
| 85730 | <1% | 919 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,084 | $3K |
| 93017 | <1% | 12 | $2K | |
| 87088 | <1% | 510 | $2K | |
| 86140 | <1% | 541 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $2K |
| 82553 | <1% | 555 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $2K |
| 96376 | <1% | 750 | $2K | |
| 80143 | <1% | 175 | $2K | |
| 84439 | <1% | 237 | $2K | |
| 80179 | <1% | 156 | $1K | |
| 93971 | <1% | 14 | $1K | |
| 94729 | <1% | 40 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,498 | $1K |
| 80053 | Comprehensive metabolic panel | <1% | 143 | $1K |
| 94060 | <1% | 14 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 50 | $946.13 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,015 | $904.93 |
| 86850 | <1% | 241 | $903.36 | |
| 82565 | <1% | 245 | $779.17 | |
| 82962 | <1% | 615 | $748.84 | |
| 82570 | <1% | 153 | $729.70 | |
| 85379 | <1% | 130 | $724.64 | |
| 93226 | <1% | 15 | $690.38 | |
| 94762 | <1% | 69 | $642.82 | |
| 73110 | <1% | 12 | $567.13 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 33 | $566.30 |
| 86900 | <1% | 281 | $557.07 | |
| 85651 | <1% | 153 | $550.86 | |
| 73564 | <1% | 56 | $546.40 | |
| 86901 | <1% | 280 | $518.99 | |
| 73502 | <1% | 14 | $502.01 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,629 | $499.98 |
| 97161 | <1% | 14 | $480.19 | |
| 73130 | <1% | 33 | $456.70 | |
| 87480 | <1% | 36 | $406.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,523 | $397.18 |
| 82728 | <1% | 41 | $386.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,570 | $382.40 |
| 94726 | <1% | 12 | $380.00 | |
| 87510 | <1% | 36 | $362.57 | |
| 87650 | <1% | 15 | $307.48 | |
| 90715 | <1% | 12 | $299.47 | |
| 84702 | <1% | 22 | $295.80 | |
| 84450 | <1% | 62 | $289.44 | |
| 82043 | <1% | 41 | $262.37 | |
| 84460 | <1% | 61 | $257.21 | |
| 87660 | <1% | 15 | $142.31 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,956 | $124.21 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,115 | $121.06 |
| 85652 | <1% | 53 | $119.88 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 16 | $105.70 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 142 | $102.62 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,953 | $99.48 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,827 | $87.54 |
| 85014 | <1% | 47 | $77.44 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,256 | $75.56 |
| 82150 | <1% | 13 | $71.62 | |
| 83550 | <1% | 13 | $48.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 562 | $46.72 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,131 | $45.79 |
| 88738 | <1% | 12 | $44.52 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 316 | $41.46 |
| 84550 | <1% | 17 | $38.18 | |
| 83540 | <1% | 13 | $35.67 | |
| 81003 | <1% | 16 | $29.84 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 520 | $29.01 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 321 | $15.08 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 146 | $6.54 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 12 | $3.22 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 177 | $3.12 |
| A9270 | Non-covered item or service | <1% | 888 | $2.85 |
| J3490 | Unclassified drugs | <1% | 352 | $1.41 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 181 | $0.69 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 101 | $0.35 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,556 | $0.01 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 1,475 | $0.01 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 95 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 84 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 63 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 47 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 43 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 33 | $0.00 |
| 94761 | 0% | 164 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 12 | $0.00 |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLETT, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.